Elevated serum ferritin what should gps know?

Australian Family Physician

Volumn 41, Issue 12, 2012, Pages 945-949

  Goot, Katie ^a   Hazeldine, Simon ^b   Bentley, Peter ^c   Olynyk, John ^b   Crawford, Darrell ^d  

^a UQ Rural Clinical School   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Haemochromatosis; Iron; Venesection

Indexed keywords

FERRITIN; IRON; TRANSFERRIN;

ARTICLE; AUSTRALIA; BLOOD; DIFFERENTIAL DIAGNOSIS; DRINKING BEHAVIOR; GENETICS; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; LIVER DISEASE; METABOLIC SYNDROME X; METABOLISM; OBESITY; PATIENT REFERRAL; PHLEBOTOMY; RED CROSS;

ALCOHOL DRINKING; AUSTRALIA; DIAGNOSIS, DIFFERENTIAL; FERRITINS; HEMOCHROMATOSIS; HUMANS; IRON; IRON OVERLOAD; LIVER DISEASES; METABOLIC SYNDROME X; OBESITY; PHLEBOTOMY; RED CROSS; REFERRAL AND CONSULTATION; TRANSFERRIN;

EID: 84871140662     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bell B. Australian Red Cross Blood Service Referrals Database. National Office, 17 O'Riordan Street Alexandria NSW [Accessed 20 April 2012].
2. Beaton MD, Adams PC. Treatment of hyperferritinemia. Ann Hepatol 2012;11:294-300.
3. Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002.
4. H ouschyar KS, Ludtke R, Dobos GJ, et al. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med 2012;10:54.
5. Valenti L, Moscatiello S, Vanni E, et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling: a propensity score-adjusted observational study. QJM 2011;104:141-9.
6. Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol 2011;55:453-8.
7. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003;361:669-73.
8. Allen K. Hereditary haemochromatosis - diagnosis and management. Aust Fam Physician 2010;39:938-41.
9. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007;46:1291-301.
10. Gurrin LC, Bertalli NA, Dalton GW, et al. HFEC282Y/ H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009;50:94-101.
11. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002;122:646-51.
12. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
13. Centers for Disease Control and Prevention. Hemochromatosis for health care professionals. Available at www.cdc.gov/ncbddd/hemochromatosis/ training/pdf/hemochromatosis_course.pdf [Accessed 11 July 2012].
14. Dale JC, Burritt MF, Zinsmeister AR. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. Am J Clin Pathol 2002;117:802-8.
15. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.
16. St John AT, Stuart KA, Crawford DHG. Testing for HFE-related haemochromatosis. Australian Prescriber 2011;34:73-6.
17. Olynyk JK, Gan E, Tan T. Predicting iron overload in hyperferritinemia. Clin Gastroenterol Hepatol 2009;7:359-62.
18. L eggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem 1990;36:1350-5.
19. Rossi E, Bulsara MK, Olynyk JK, Cullen DJ, Summerville L, Powell LW. Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. Clin Chem 2001;47:202-8.
20. Brudevold R, Hole T, Hammerstrom J. Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload. PLoS One 2008;3:e3547.
21. Trombini P, Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. J Hepatol 2007;46:549-52.
22. Chew GT, Gan SK, Watts GF. Revisiting the metabolic syndrome. Med J Aust 2006;185:445-9.
23. Pietrangelo A. Iron in NASH, chronic liver diseases and HCC: How much iron is too much? J Hepatol 2009;50:249-51.
24. Wong K, Adams PC. The diversity of liver diseases among outpatient referrals for an elevated serum ferritin. Can J Gastroenterol 2006;20:467-70.